Dupixent Cancer Lawsuits Update (Aug. 2026)
Dupixent Cancer Lawsuits Update: are being filed and investigated against Dupixent (dupilumab) manufacturers Sanofi and Regeneron, alleging the biologic drug increases the risk of cutaneous T-cell lymphoma (CTCL) and other T-cell lymphomas, or can “mask” early cancer symptoms, and that the companies failed to provide adequate warnings.
Current Status of the Dupixent Lawsuits
- Individual Lawsuits: Plaintiffs across the U.S. are currently filing individual product liability and wrongful death claims.
- Early Stages: The litigation is growing, and individual personal injury and wrongful death lawsuits have been filed in federal courts.
- Multidistrict Litigation (MDL): A federal multidistrict litigation (MDL) was established by the Judicial Panel on Multidistrict Litigation in June 2026 to coordinate similar claims before a single judge.
- No Settlements Yet: There have been no trials, jury verdicts, or nationwide class-action settlements finalized
The Medical and Regulatory Context
- The Concern: Cutaneous T-cell lymphoma (CTCL) is a rare blood cancer that affects white blood cells and can initially look like a stubborn red, scaly eczema rash. Plaintiffs claim Dupixent can accelerate the disease or hide its signs by clearing surface inflammation while the underlying cancer progresses.
- FDA Monitoring: Following hundreds of adverse event reports noting T-cell lymphoma diagnoses in patients using the drug, the U.S. Food and Drug Administration (FDA) has been evaluating safety signals and potential label updates
Key Allegations and Evidence
- Failure to Warn: Lawsuits claim the manufacturers knew or should have known about the lymphoma risk from post-marketing data and clinical studies but did not update the drug’s label.
- Scientific Research: A 2024 study published in Dermatologic Therapy found that patients treated with Dupixent were more than four times as likely to develop CTCL compared to those who never received the drug.
- FDA Action: In March 2025, the FDA issued a Newly Identified Safety Signal (NISS) and launched a formal investigation after receiving hundreds of adverse event reports regarding CTCL and other lymphomas in Dupixent users.
Contact Nashville Dupixent Cancer Lawyer Timothy L. Miles who can tell you if you are eligible for a Dupixent Cancer Lawsuit and can explain more about the type of damages you are entitled to receive. (855) 846–6529 or [email protected].
Who May Qualify for a Dupixent Lawsuit
While legal evaluations depend heavily on individual medical records, those whe meet the following criteria for a Dupixent Cancer Lawsuit maybe be quality:
- Were prescribed and used Dupixent for eczema, asthma, or another approved condition.
- Were subsequently diagnosed with cutaneous T-cell lymphoma (CTCL), mycosis fungoides, Sézary syndrome, or another T-cell malignancy during or shortly after treatment.
- Did not have a prior history of this specific cancer before starting the medication.
- Families of individuals who suffered fatal complications from lymphoma after taking Dupixent may qualify to file wrongful death actions.
Research and the Link Between Dupixent and Cancer
April 2024 Retrospective Study
A 2024 retrospective study published in Dermatologic Therapy reported that eczema patients treated with Dupixent (dupilumab) had a relative risk of 4.59 for developing cutaneous T-cell lymphoma (CTCL) compared to untreated controls. Similar odds ratios have been noted in other concurrent literature, though experts debate whether the drug causes the cancer or merely unmasks an early, misdiagnosed case.
Study Details and Findings
- The Data: Researchers analyzed large health data cohorts comparing atopic dermatitis patients taking dupilumab against untreated patients.
- Risk Multiplier: The relative risk calculated was approximately 4.59 times higher in the treated group.
- Timing: A notable portion of diagnoses occurred within the first year of starting the therapy, though other cohorts noted diagnoses stretching past one year.
- Patient Age: Over half of the CTCL cases in the treated group occurred in adults over age 60.
The “Unmasking” Debate
- Symptom Suppression: Early-stage CTCL (like mycosis fungoides) looks and acts very much like severe eczema.
- Diagnostic Delay: Doctors note that suppressing skin inflammation can make underlying, undetected lymphoma cells harder to spot initially.
- Causality Unproven: Retrospective database studies show an association, but they do not definitively prove that Dupixent directly mutates cells to cause cancer.
August 2024 Retrospective Study
- The Study: A study published on April 6, 2024 (Hasan et al., 2024), looked at whether people with atopic dermatitis (AD) who were treated with the drug dupilumab had a higher risk of developing cutaneous T-cell lymphoma (CTCL) compared to those who didn’t take the drug
- Three Hundred Percent Risk Increase: In their first model, which adjusted for age only, they found that people who took dupilumab had a 300% higher risk of getting CTCL compared to those who didn’t (OR 4.10).
- Risk Increase after Profile Adjustments: Even after they adjusted for more factors—like sex, ethnicity, and race, and removed people who had taken certain other immune-suppressing drugs—the risk was still more than two times higher (OR 3.20).
2025 Population Based Cohort Study
- Study Method: In September 2025, a study led by Sheng-Kai Ma and his team looked at the patients in the United States with asthma who initiated dupilumab or the active comparator (combination therapy with inhaled corticosteroids (ICS) plus long-acting β-agonists (LABA), or ICS/LABA), between 2018 and 2024.
- Results of Study: After propensity score matching, dupilumab-treated patients were found to have a higher risk of lymphoma (54 versus 43 cases, hazard ratio (HR) 1.79, 95% CI 1.19-2.71), especially T-cell and natural killer (NK)-cell lymphomas (19 versus ≤10 cases, HR 4.58, 95% CI 1.82-11.53).
- Results after Profile Adjustments:After adjusting for things like age, gender, income, other health problems, and medicine use, the risk of CTCL was more than 4.5 times higher in the dupilumab group.
- Resuls of Patients After Sixteeen Weeks Dosing: Dupilumab was also linked to an overall increased risk of any type of lymphoma. When the researchers looked only at patients who had taken their medications for at least 16 weeks, the risk numbers went up even more, especially for combined mature T and NK cell lymphomas, a broader group of cancers including CTCL and other subtypes, which was over 14 times higher for dupilumab users.
2019 CTCL Acceleration Study
- The Study: A 2019 study published in the Nation Library of Medicine, Acceleration of cutaneous T-cell lymphoma following dupilumab administration, showed multiple patients saw CTCL symptoms accelerate while using dupilumab.
- Unmasking of Hidden Lymphomas: Case reports warning that Dupixent may “unmask” or worsen hidden lymphomas mistaken for eczema.
- Study Conclusion:
Increased awareness and reporting are essential for improving understanding and providing comprehensive and individualized care to patients. We advocate for the diligent monitoring of disease course after dupilumab initiation. At the first sign of inadequate treatment response, there must be prompt evaluation for CTCL and alternative diagnoses, particularly in patients with skin of color.
Russomanno K, Carver DeKlotz CM. Acceleration of cutaneous T-cell lymphoma following dupilumab administration. JAAD Case Rep. 2020 Dec 17;8:83-85. doi: 10.1016/j.jdcr.2020.12.010. PMID: 33532533; PMCID: PMC7829113 (emphasis supplied).
Contact Nashville Dupixent Cancer Lawyer Timothy L. Miles who can tell you if you are eligible for a Dupixent Cancer Lawsuit and can explain more about the type of damages you are entitled to receive. (855) 846–6529 or [email protected].
Patient Reports of Cancer Linked to Dupixent
- Patient and Healthcare Reports on FAERS: In addition to the clinical research and studies, the U.S. Federal and Drug Administration’s (FDA), Adverse Event Reporting System (FAERS) included numerous patient reports and reports from healthcare providers linking Dupixent (dupilumab) to cancer, specifically to multiple types of T-cell lymphoma. FAERS is a vital database that regulators and researchers use to recognize potential drug risks requiring further investigation.
- Reports Confirm Clinical Research: the current dashboard shows close to 300 reports of T-cell lymphoma cases among Dupixent patients, which includes confirmed reports of cutaneous T-cell lymphoma (CTCL) and other related and serious conditions. These patient and healthcare reports to the FDA continue to fuel concerns that was addressed in clinical studies, strengthening the need for doctors to closely monitoring patients taking Dupixent.
- The database shows the following type of cases have been reported by patients taking Dupixent or reported by healthcare providers:
-
- Cutaneous T-Cell Lymphoma
- Adult T-Cell Lymphoma/Leukemia
- T-Cell Lymphoma (general)
- CTCL, Stage IV
- CTCL, Stage III
- Angioimmunoblastic T-Cell Lymphoma
- CTCL, Stage I
- Recurrent T-Cell Lymphoma
- Lymphoma (unspecified)
- Anaplastic Large Cell Lymphoma (T- and null-cell types)
- Unclassifiable T-Cell Lymphoma
Volume of Reports: The vast volume of these reports only provides further evidence that Dupixent may be contributing to serious cancer risks in certain patients.
Post Marketing Data: What “Real World” Monitoring Adds
Once a drug is approved, safety monitoring continues through:
- Spontaneous adverse event reporting systems
- Claims based observational studies
- Specialty registries
- Institutional and national pharmacovigilance programs
This real world evidence is valuable because it includes:
- Longer follow up
- Broader patient demographics
- Patients with prior malignancy or higher baseline risk
The tradeoff is that real world data is often observational. It can identify signals but cannot always prove causality because of confounding factors such as:
- Prior immunosuppressant exposure (common in severe eczema)
- Smoking history (relevant for lung and head and neck cancers)
- Age and family history
- Disease severity and chronic inflammation itself
The Special Case: Cutaneous T Cell Lymphoma (CTCL) and “Misdiagnosed Eczema”
The most discussed and clinically relevant malignancy topic involving dupil
umab is cutaneous T cell lymphoma (CTCL), including mycosis fungoides and Sézary syndrome. This is not because Dupixent has been proven to cause CTCL, but because of a recurring real world clinical scenario:
- A patient has a chronic, treatment resistant dermatitis that resembles eczema.
- Dupixent is started.
- The rash does not improve as expected, or changes character.
- Further evaluation reveals CTCL that was present but not recognized earlier.
Why this happens
CTCL can mimic eczema for years. Early lesions may look like:
- Persistent patches or plaques
- Eczematous dermatitis with itch
- Variable distribution and incomplete response to topical therapies
When a patient has “eczema” that behaves atypically, CTCL enters the differential diagnosis.
Key Warning Signs for Dupixent and Cancer
Severe Eczema Patients Be Vigilant: For individuals using Dupixent for severe eczema, the diagnostic challenge is compounded because the drug’s anti-inflammatory action may temporarily mask or alter the appearance of early CTCL symptoms.
- Be Aware of Warning Signs Early: Warning signs that may differentiate CTCL from typical eczema in Dupixent users include:
-
- Failure to respond to treatment: Rashes or lesions that persist, worsen, or spread despite ongoing Dupixent use should raise suspicion of an underlying condition.
-
- Progression to plaques and tumors: The development of thicker, raised lesions (plaques) or lumps/nodules (tumors) that can ulcerate is a sign of advancing CTCL not typically seen in standard eczema.
-
- Development of systemic symptoms: Advanced CTCL can lead to symptoms not associated with eczema, such as persistently swollen lymph nodes (in the neck, armpits, or groin), unexplained fatigue, or weight loss.
-
- Sudden acceleration of symptoms: In some case reports, patients experienced a rapid worsening of skin changes shortly after starting Dupixent, suggesting the drug may accelerate the progression of an undetected lymphoma.
-
- Skin Changes and Seeking Immediate Medical Help: If you notice persistent or unusual skin changes while on Dupixent, it is crucial to seek a medical evaluation, including a skin biopsy reviewed by a specialist familiar with cutaneous lymphomas
Scientific Evidence and Regulatory Action
- FDA Investigation: The FDA is formally investigating the potential safety signal for CTCL linked to Dupixent use. This investigation began in March 2025.
- Cause of investigation: The FDA’s investigation was prompted by a significant number of adverse event reports linking Dupixent to cutaneous T-cell lymphoma (CTCL).
- Allegations: A Dupixent Lawsuit against the manufacturers claim they failed to adequately warn patients and doctors about this potential risk.
- Status: The FDA has not recalled Dupixent, but the investigation is formal and follows a pattern of regulatory actions that may include label revisions.
- Adverse Event Reports: The FDA’s Adverse Event Reporting System (FAERS) has received hundreds of reports of lymphoma among Dupixent users.
- Increased Risk Studies: Several peer-reviewed studies suggest an increased risk of Dupixent and Cancer.
Who is Eligible for a Dupixent Cancer Lawsuit?
Dupixent Cancer Lawsuit: You may qualify for a Dupixent Cancer Lawsuit if:
- Used Dupixent (dupilumab) as prescribed
- Were later diagnosed with T-Cell Lymphoma, especially Cutaneous T-Cell Lymphoma
- Experienced serious Dupixent side effects or worsening symptoms
- Are within your state’s statute of limitations
To see if your case may be timely in the state you reside in, please see our Statutes of Limitations Calulators for further informaton.
STATUTE OF LIMITATIONS CALCULATORS
Compensation in a Dupixent Cancer Lawsuit
If you are eligible for a Dupixent Cancer Lawsuit, a successful plaintiff is entitled to compensatory damages which would include compensation for things such as:
- past and future medical expenses;
- pain and suffering including emotional distress; and
- lost wages and the reduction in your ability to earn an income.
If your case proceeds to trial it is also possible the court could impose punitive damages, intended to punish the defendant for their actions. ContactNashville Dupixent Cancer LawyerTimothy L. Miles who can tell you if you are eligible for a Dupixent Cancer Lawsuit and can explain more about the type of damages you are entitled to receive. (855) 846–6529 or [email protected].
What the FDA Labeling and Safety Communications Generally Emphasize
Drug labels evolve as evidence accumulates. In general, regulatory labeling for dupilumab has historically emphasized:
- Conjunctivitis and ocular surface disease in some populations
- Injection site reactions
- Eosinophilia and rare eosinophilic conditions
- Hypersensitivity reactions
- Helminth infection considerations
Cancer is not typically presented as a primary established risk. However, there are ongoing discussions about Dupixent and its potential cancer risk, which clinicians should always check the most current prescribing information and safety updates, because labeling is the definitive regulatory source.
If you believe you qualify for a Dupixent Cancer Lawsuit, contact Dupixent Cancer Lawyer Timothy L. Miles for a free case evaluation to see if you are eligible for a Dupixent Cancer Lawsuit and possible entitled to substantial compensation. 855/846-6529 or via e-mail at [email protected].(24/7/365).
Frequently Asked Questions (FAQ) about Dupixent and Cancer Risks
Does Dupixent suppress the immune system and cause cancer like other biologics?
Dupixent is an immune modulator targeting IL 4 and IL 13 signaling. It is not generally categorized as a broad immunosuppressant. As of 2026, evidence does not show a clear increased overall cancer risk, but long term rare event uncertainty remains. However, some patients have raised concerns about potential links between Dupixent and cancer, leading to Dupixent cancer lawsuits being filed.
Should I avoid Dupixent if cancer runs in my family?
Family history increases baseline risk for certain cancers, such as those linked to BRCA gene mutations. It does not automatically contraindicate Dupixent. The decision should focus on your personal risk profile, your disease severity, and available alternatives. If you have concerns about using Dupixent due to family cancer history, it may be beneficial to consult with a Dupixent cancer lawyer who can provide legal advice based on your specific circumstances.
If I develop cancer while on Dupixent, did Dupixent cause it?
A cancer diagnosis during treatment does not prove causation. Many cancers arise from long term processes unrelated to a recent medication change. Your care team will evaluate cancer type, timeline, other risk factors, and whether continuation is appropriate during treatment. If you suspect that Dupixent may have contributed to your cancer diagnosis, you might want to explore Dupixent cancer claims, which could provide avenues for legal recourse depending on the specifics of your situation.
What is the main cancer related issue doctors watch for with Dupixent?
The most actionable issue is the possibility of CTCL being misdiagnosed as eczema, leading to delayed diagnosis. Persistent non response, atypical lesions, or systemic signs should prompt reconsideration and possible biopsy.
What is Dupixent and for which conditions is it prescribed?
Dupixent (dupilumab) is a targeted biologic therapy that inhibits interleukin 4 (IL-4) and interleukin 13 (IL-13) signaling by binding to the IL-4 receptor alpha subunit. It is prescribed for chronic inflammatory diseases driven by type 2 inflammation, including atopic dermatitis (eczema), asthma with eosinophilic or allergic phenotype, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and certain cases of chronic obstructive pulmonary disease.
Does Dupixent increase the risk of developing cancer?
Current evidence from pivotal clinical trials, long-term extension studies, and post-marketing safety monitoring indicates that Dupixent has not demonstrated a clear or consistent increase in overall cancer incidence compared to expected background rates. While no strong evidence suggests Dupixent meaningfully increases cancer risk, many trials were not specifically powered to detect small changes in risk and cancers with long latency periods require further study.
How does Dupixent’s mechanism of action relate to Dupixent and Cancer Risks?
Dupixent selectively modulates the immune system by inhibiting IL-4 and IL-13 signaling pathways involved in type 2 inflammation rather than causing broad immunosuppression. Since the immune system plays a role in tumor surveillance, broad immunosuppressants can increase cancer risk; however, Dupixent’s targeted immune modulation does not globally suppress immune function, which is central to interpreting its potential cancer risk.
Have there been a Dupixent Lawsuit related to Dupixent and cancer risk?
Yes, there have been lawsuits filed alleging that Dupixent may be associated with an increased risk of certain cancers. These legal actions highlight concerns from patients and caregivers regarding potential severe adverse effects related to cancer following Dupixent use. It is important for patients considering legal action to understand the compensation process and qualification criteria for such lawsuits.
Contact Timothy L. Miles Today About a Dupixent Cancer Lawsuit
Contact Timothy L. Miles Today About a Dupixent Cancer LawsuitIf you believe you qualify for a Dupixent Cancer Lawsuit, contact Dupixent Cancer Lawyer Timothy L. Miles for a free case evaluation to see if you are eligible for a Dupixent Cancer Lawsuit and possible entitled to substantial compensation. 855/846-6529 or via e-mail at [email protected]. (24/7/365).
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com